Free for academic non-profit institutions. Other users need a Commercial license
This gene encodes a member of the cGMP-inhibited cyclic nucleotide phosphodiesterase (cGI-PDE) family. cGI-PDE enzymes hydrolyze both cAMP and cGMP, and play critical roles in many cellular processes by regulating the amplitude and duration of intracellular cyclic nucleotide signals. The encoded protein mediates platelet aggregation and also plays important roles in cardiovascular function by regulating vascular smooth muscle contraction and relaxation. Inhibitors of the encoded protein may be effective in treating congestive heart failure. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Sep 2011]
PDE3A (Phosphodiesterase 3A) is a Protein Coding gene. Diseases associated with PDE3A include Hypertension And Brachydactyly Syndrome and Brachydactyly. Among its related pathways are Sweet Taste Signaling and Signal transduction_PKA signaling. Gene Ontology (GO) annotations related to this gene include 3',5'-cyclic-nucleotide phosphodiesterase activity and 3',5'-cyclic-AMP phosphodiesterase activity. An important paralog of this gene is PDE3B.
Phosphodiesterases (PDEs) are a family of phosphohydrolyases that catalyze the hydrolysis of 3' cyclic phosphate bonds in adenosine and/or guanine 3',5' cyclic monophosphate (cAMP and/or cGMP). PDEs regulate the second messengers by controlling their degradation.
GeneHancer (GH) Identifier | GH Type | GH Score |
GH Sources | Gene Association Score | Total Score | TSS distance (kb) | Number of Genes Away | Size (kb) | Transcription Factor Binding Sites |
Gene Targets |
---|---|---|---|---|---|---|---|---|---|---|
GH12J020367 | Promoter/Enhancer | 2.1 | EPDnew Ensembl ENCODE CraniofacialAtlas dbSUPER | 600.7 | +3.5 | 3526 | 8.9 | PRDM10 KDM1A CTCF PRDM1 ZIC2 PATZ1 POLR2A EZH2 ZNF341 CEBPB | ENSG00000256879 PDE3A UBE2L2 SLCO1C1 | |
GH12J020272 | Promoter | 0.4 | EPDnew | 600.2 | -96.2 | -96177 | 0.1 | NR3C1 | PDE3A HSALNG0089736 lnc-SLCO1A2-2 AEBP2 | |
GH12J020366 | Enhancer | 0.4 | dbSUPER | 608 | -1.5 | -1544 | 0.5 | RCOR1 CHD2 POLR2A | PDE3A ENSG00000256879 LOC105369688 AEBP2 | |
GH12J020320 | Promoter | 0.3 | EPDnew | 623.1 | -47.7 | -47741 | 0.1 | PDE3A LOC105369688 HSALNG0089736 AEBP2 | ||
GH12J020300 | Promoter | 0.3 | EPDnew | 600.2 | -67.8 | -67845 | 0.1 | PDE3A HSALNG0089736 LOC105369688 AEBP2 |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0004114 | 3',5'-cyclic-nucleotide phosphodiesterase activity | IEA | -- |
GO:0004115 | 3',5'-cyclic-AMP phosphodiesterase activity | IEA,IBA | 21873635 |
GO:0004119 | cGMP-inhibited cyclic-nucleotide phosphodiesterase activity | TAS | 9173884 |
GO:0005515 | protein binding | IPI | 19332778 |
GO:0008081 | phosphoric diester hydrolase activity | IEA | -- |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0005829 | cytosol | IEA,TAS | -- |
GO:0016020 | membrane | IEA | -- |
GO:0016021 | integral component of membrane | IEA | -- |
SuperPathway | Contained pathways | ||
---|---|---|---|
1 | Activation of cAMP-Dependent PKA |
Activation of cAMP-Dependent PKA
.77
cAMP Pathway
.77
|
Activation of PKA through GPCR
.71
PKA Signaling
.56
|
2 | Sweet Taste Signaling |
Sweet Taste Signaling
.72
Cellular Effects of Sildenafil
.46
|
Bitter Taste Signaling
.44
Sperm Motility
.37
|
3 | Signaling by GPCR | ||
4 | Nitric oxide stimulates guanylate cyclase |
.01
|
|
5 | cAMP signaling pathway |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0001556 | oocyte maturation | IBA | 21873635 |
GO:0006629 | lipid metabolic process | TAS | 8921398 |
GO:0007165 | signal transduction | IEA | -- |
GO:0007186 | G protein-coupled receptor signaling pathway | TAS | -- |
GO:0019933 | cAMP-mediated signaling | IBA,IMP | 17704206 |
Name | Status | Disease Links | Group | Role | Mechanism of Action | Clinical Trials |
---|---|---|---|---|---|---|
Milrinone | Approved | Pharma | Inhibitor, Inhibition, Target, inhibitor | PDE-3 inhibitor | 49 | |
Cilostazol | Approved, Investigational | Pharma | Target, inhibitor | PDE3 inhibitor | 126 | |
Amrinone | Approved | Pharma | Target, inhibitor | 0 | ||
Anagrelide | Approved | Pharma | Target, inhibitor | 27 | ||
Enoximone | Approved, Investigational | Pharma | Target, inhibitor | 6 |
Name | Synonyms | Role | CAS Number | PubChem IDs | PubMed IDs | |
---|---|---|---|---|---|---|
Eggmanone |
|
505068-32-6 |
|
|
||
Etazolate hydrochloride |
|
35838-58-5 |
|
|
||
IBMX |
|
Antagonist | 28822-58-4 |
|
|
|
MY-5445 |
|
78351-75-4 |
|
|
||
Ro 20-1724 |
|
29925-17-5 |
|
|
Compound | Action | Cas Number |
---|---|---|
Eggmanone | Potent and selective PDE4 inhibitor; suppresses hedgehog signaling | 505068-32-6 |
Etazolate hydrochloride | PDE4 inhibitor | 35838-58-5 |
IBMX | PDE inhibitor (non-selective) | 28822-58-4 |
MY-5445 | PDE5 inhibitor | 78351-75-4 |
Ro 20-1724 | PDE4 inhibitor | 29925-17-5 |
Compound | Action | Cas Number |
---|---|---|
Cilostazol | PDE3 inhibitor | 73963-72-1 |
Dipyridamole | 58-32-2 | |
Milrinone | PDE-3 inhibitor | 78415-72-2 |
Olprinone Hydrochloride | Phosphodiesterase 3 (PDE3) inhibitor, selective | 119615-63-3 |
Pimobendan | Selective PDE3 inhibitor.Ca2+ channel sensitizer | 74150-27-9 |
Sildenafil Citrate | Treat erectile dysfunction and PAH | 171599-83-0 |
Zardaverine | PDE III and IV inhibitor | 101975-10-4 |
This gene was present in the common ancestor of chordates.
Organism | Taxonomy | Gene | Similarity | Type | Details |
---|---|---|---|---|---|
Chimpanzee (Pan troglodytes) |
Mammalia | PDE3A 30 31 |
|
OneToOne | |
Dog (Canis familiaris) |
Mammalia | PDE3A 30 31 |
|
OneToOne | |
Cow (Bos Taurus) |
Mammalia | PDE3A 30 31 |
|
OneToOne | |
Mouse (Mus musculus) |
Mammalia | Pde3a 30 17 31 |
|
OneToOne | |
Rat (Rattus norvegicus) |
Mammalia | Pde3a 30 |
|
||
Oppossum (Monodelphis domestica) |
Mammalia | PDE3A 31 |
|
OneToOne | |
Platypus (Ornithorhynchus anatinus) |
Mammalia | PDE3A 31 |
|
OneToOne | |
Chicken (Gallus gallus) |
Aves | PDE3A 30 31 |
|
OneToOne | |
Lizard (Anolis carolinensis) |
Reptilia | PDE3A 31 |
|
OneToOne | |
Zebrafish (Danio rerio) |
Actinopterygii | pde3a 30 31 |
|
OneToOne | |
Dr.11181 30 |
|
||||
Sea Squirt (Ciona savignyi) |
Ascidiacea | -- 31 |
|
OneToMany |
SNP ID | Clinical significance and condition | Chr 12 pos | Variation | AA Info | Type |
---|---|---|---|---|---|
690366 | Likely Pathogenic: Brachydactyly-arterial hypertension syndrome | 20,616,283(+) | GACC/G | INFRAME_DELETION | |
709508 | Benign: not provided | 20,621,383(+) | T/C | SYNONYMOUS_VARIANT | |
713015 | Benign: not provided | 20,648,864(+) | T/C | SYNONYMOUS_VARIANT | |
717258 | Benign: not provided | 20,369,515(+) | G/A | SYNONYMOUS_VARIANT | |
717311 | Benign: not provided | 20,369,602(+) | A/G | SYNONYMOUS_VARIANT |
Variant ID | Type | Subtype | PubMed ID |
---|---|---|---|
dgv258e214 | CNV | gain | 21293372 |
dgv775e59 | CNV | tandem duplication | 20981092 |
esv1015874 | CNV | deletion | 17803354 |
esv1326828 | CNV | insertion | 17803354 |
esv1692681 | CNV | insertion | 17803354 |
esv2218919 | CNV | deletion | 18987734 |
esv2663850 | CNV | deletion | 23128226 |
esv2668063 | CNV | deletion | 23128226 |
esv2674271 | CNV | deletion | 23128226 |
esv2745621 | CNV | deletion | 23290073 |
esv3405393 | CNV | duplication | 20981092 |
esv3580173 | CNV | loss | 25503493 |
esv3628787 | CNV | loss | 21293372 |
esv5808 | CNV | gain | 19470904 |
nsv1042315 | CNV | gain | 25217958 |
nsv1054997 | CNV | gain | 25217958 |
nsv1159988 | CNV | duplication | 26073780 |
nsv469158 | CNV | loss | 19166990 |
nsv557701 | CNV | loss | 21841781 |
nsv557702 | CNV | loss | 21841781 |
nsv557703 | CNV | loss | 21841781 |
nsv634 | CNV | insertion | 18451855 |
nsv976582 | CNV | duplication | 23825009 |
Disorder | Aliases | PubMed IDs |
---|---|---|
hypertension and brachydactyly syndrome |
|
|
brachydactyly |
|
|
impotence |
|
|
acrodysostosis |
|
|
familial hypertension |
|
|